Mark Rubin
Ophthalmology · Ormond Beach, FLNPI 1114943131
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (38.5%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Perrigo Company PLC at 42.9% of the total. Reporting peaked in 2019 at $2,524 and has fallen 98.1% since, to $48 in 2025.
Across 54 payments — averaging $94.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Perrigo Company PLC$2K
- Bristol Myers Squibb$1K
- Kala Pharmaceuticals, Inc.$264
- NEW World Medical,inc.$194
- Aerie Pharmaceuticals, Inc.$184
- Sight Sciences, Inc.$163
- plus $698 from 13 others
Across 9 payments — averaging $5757.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ocular Therapeutix, Inc.$26K
- Bausch Health US, LLC$24K
- Perrigo Company PLC$3K
What the payments were for
- Consulting fees$1,41328%
- Travel & lodging$1,67933%
- Food & beverage$1,96638%
- Education$110%
- Gifts$391%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Perrigo Company PLC | 2 | $2,192 |
| Bristol Myers Squibb | 1 | $1,413 |
| Kala Pharmaceuticals, Inc. | 8 | $264 |
| NEW World Medical,inc. | 4 | $194 |
| Aerie Pharmaceuticals, Inc. | 3 | $184 |
| Sight Sciences, Inc. | 3 | $163 |
| E.r. Squibb & Sons, L.L.C. | 8 | $150 |
| Alcon | 5 | $101 |
| Novartis | 4 | $85 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $84 |
| Johnson & Johnson | 4 | $62 |
| Pfizer | 2 | $50 |
| Sun Pharmaceutical Industries Inc. | 2 | $45 |
| Carl Zeiss Meditec AG | 2 | $39 |
| GSK | 1 | $20 |
| Bausch & Lomb Americas Inc. | 1 | $19 |
| Biotissue Holdings Inc. | 1 | $17 |
| Eyevance Pharmaceuticals LLC | 1 | $14 |
| Blueprint Medicines Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Reblozyl$1,413
- INVELTYS$125
- OMNI(R) SURGICAL SYSTEM (US)$125
- Rhopressa$101
- Rocklatan$101
How this compares
$5,107 in reported general payments places this provider in the 75th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Ormond Beach
- Cathleen McCabeBradenton$2M
- Daniel KiernanSarasota$1.7M
- David EichenbaumSt Petersburg$1.7M
- Mark MilnerPalm Beach Gardens$1.2M
- Neel DesaiLargo$1M
- Jorge FortunPalm Beach Gardens$798K
- Courtney BoveeTampa$796K
- Harold BrooksTallahassee$683K
- Robert WeinstockLargo$605K
- William TrattlerMiami$579K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.